Establishment and application of DUE criteria for IV administration of voriconazole

doi:10.12092/j.issn.1009-2501.2018.12.018

Abstract

Abstract:

AIM: To establish the drug use evaluation(DUE) for intravenous injection (IV) administration of voriconazole and to provide reference for rational use of voriconazole. METHODS: According to voriconazole instructions and relative references, DUE criteria for IV administration of voriconazole were established. A total of 121 cases from July 2017 to July 2018 were retrospectively evaluated by the established evaluation and analyzed in respects of medication indication, medication duration, medication results, management indexes, etc. RESULTS: The results for DUE of voriconazole was that the coincidence rate of medication indication was 66.9%(target value was 90%), the rates of administration, solvent selections and preparation methods were all 100%(target value was 100%), the rates of dosage and course of treatment were 31.4% and 81.0% (target value was 95%), microbial inspection rate was 43.8%(target value was 80%),the effective rate of drug use was 50.4% (target value was 80%) and the compliance rate of authority management was 73.6% (target value was 100%). CONCLUSION: Established DUE criteria of IV administration of voriconazole can evaluate and standardize the clinical utilization of voriconazole.

Key words: voriconazole, rational use of drug, drug use evaluation

CLC Number:

LI Hao, CHENG Juan, ZHENG Xiaoqing, ZHANG Lei, ZHU Na, ZHOU Chengyue, WU Jian. Establishment and application of DUE criteria for IV administration of voriconazole[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1420-1424.

References

［1］Paul RA,Rudramurthy SM,Dhaliwal M,et al.Voriconazole resistance in clinical and environmental isolates of Aspergillus flavus-frequency and investigation into the role of multidrug efflux pumps［J］.Antimicrob Agents Chemother,2018 Aug 20.pii:AAC.01022-18.
［2］郭青青.2012-2014年医院获得性深部真菌感染的临床分布及药敏结果［J］.现代预防医学,2016,43(8) :1517-1518, 1526.
［3］李德东,单文治,胡静,等.国内临床常见致病真菌及其对唑类药物的敏感性分析［J］.中国药物应用与监测,2016,13(02):121-124.
［4］《抗菌药物临床应用指导原则》修订工作组.抗菌药物临床应用指导原则：2015年版［S］.2015-07-24.
［5］张静,何礼贤.侵袭性肺真菌病诊治指南解读［J］.中国药物应用与监测,2011,8(05):261-265.
［6］重症患者侵袭性真菌感染诊断与治疗指南(2007)［J］.中华内科杂志,2007,46(11):960-966.
［7］黄鑫炎,谢灿茂.2011年ATS成人呼吸与危重症患者真菌感染治疗指南解读［J］.中国循证医学杂志,2016,16(01):11-19.
［8］袁浩宇,林勇,胡明,等.药物利用评价标准建立的方法探讨及实践［J］.中国药房,2010,21(22): 2101-2104.
［9］张弨.伏立康唑的药效学研究评价［J］.中国临床药理学与治疗学,2018,23(1):116-120.
［10］Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in livertransplantrecipients［J］.Antimicrob Agents Chemother,2010,54(2):852-859.
［11］Abel S, Allan R, Gandelman K,et al.Pharmacokinetics,safety and tolerance of voriconazole in renally impaired subjects:two prospective,multicenter,open-label,parallel-group volunteer studies［J］.Clin Drug Investig,2008,28(7):409-420.
［12］Li TY, Liu W, Chen K ,et al.The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review［J］. J Clin Pharm Ther. 2017 Apr;42(2):135-146.
［13］刘亮,郭美华,陈岩,等.高效液相色谱法测定人血浆中伏立康唑浓度及其应用［J］.中国药物应用与监测,2017,14(4):205-208.
［14］余静洁,杨四涛,周星,等.基于伏立康唑血药浓度监测成功干预药物相互作用3例［J］.医药导报,2017,36(8):879-883.
［15］Boyd NK,Zoellner CL,Swancutt MA,等.质子泵抑制剂增高伏立康唑血药浓度［J］.中国感染与化疗杂志,2015,15(01):80.
［16］陈江飞,苗彩云,徐萍.抗真菌药伏立康唑的临床药代动力学研究进展［J］.中国临床药理学与治疗学,2015,20(9):1072-1080.
［17］Veloso DFMC, Benedetti NIGM, vila RI.et al. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity［J］. Drug Deliv, 2018, 25(1):1585-1594.
［18］詹莹,疏楠,郭楠,等.三氮唑类抗真菌药的治疗药物监测研究进展［J］.中国临床药理学与治疗学,2014,19(6):706-711.
［19］曹红.临床药物治疗学［M］.北京：人民卫生出版社, 2008.
［20］Tan EC, George J, Stewart K，et al.Improving osteoporosis management in general practice: a pharmacist-led drug use evaluation program［J］. Drugs Aging，2014，31(9):703-709.

[1]	PENG Min, HUANG Panhao, DENG Yinhua, LIU Wen, LI Wei, YU Zhen, XIA Qing, XIE Yueliang. Analysis of influence factors of voriconazole trough concentration in patients with hematopoietic stem cell transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 640-646.
[2]	WANG Yuanyuan, HONG Yu, ZHANG Lei, YIN Fangxiong, LEI Ting, ZHU Xi. Establishment and application of DUE criteria for human albumin in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 653-661.
[3]	GUO Mingxing, GUO Heng, SHEN Su, SUN Liying, CUI Xiangli. Retrospective analysis of voriconazole in the monitoring of therapeutic drugs in patients with liver dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 757-763.
[4]	LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping. Research progress in population pharmacokinetics of voriconazole in adults [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
[5]	ZHAO Quanfeng, FU Peishu, MA Huan, ZHAO Suyu, GUO Daihong, TANG Min. Study on liver dysfunction related to voriconazole by automatic surveillance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 43-48.
[6]	WANG Lili. Clinical application and rationality analysis of voriconazole injection [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 99-102.
[7]	DAI Ying, ZHANG Haina, LIN Guanyang, YU Xuben. Research progress on the population pharmacokinetics of voriconazole and its application in the design of dosage regimen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(9): 1063-1067.
[8]	ZHANG Chao . Pharmacodynamic studies evaluation of voriconazole [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 116-120.
[9]	DONG Chao, WANG Tao, ZHOU Dongmei, WANG Ya, WANG Laicheng, LV Dongmei. Investigation and analysis of antidiabetic agents therapy in inpatients with type 2 diabetes mellitus in our hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 87-91.
[10]	ZHAN Ying, SHU Nan, GUO Nan, SHAO Hua, LI Wei-lan. Advances in therapeutic drug monitoring for triazole antifungal agents [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(6): 706-711.
[11]	ZHOU Si-xi. Analysis of utilization of antihypertensive drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(4): 466-470.